Search competencies and applied modules
Ibogaine safety and risk management
Pharmacology and time course
Ibogaine Safety and Risk Management
Educational material; not a treatment relationship.
Pharmacokinetic and phenomenological timeline
Ibogaine exposure, the inward experience, and physical recovery do not follow one shared clock. Read them together while keeping the limits of each source in view.
Onset
First minutes to hours
Pharmacokinetics
Ibogaine is absorbed and converted to active noribogaine, principally through CYP2D6. In a model of 14 people with opioid use disorder, median time to peak ibogaine concentration was 0.62 hours. This is a plasma measurement, not the time of peak subjective intensity.
Absorption and the first changes
Mash and colleagues reported initial visual effects around 30 to 45 minutes after oral ibogaine in their treatment cohort. Altered sound, bodily sensations, and changes in thinking may accompany imagery. Other accounts describe different onsets or little visual content.
Support during this stage
Before the session, agree on how to get someone’s attention. As changes begin, you can keep your eyes open or closed according to comfort and the care plan. Let your facilitator know if sound, light, touch, or movement feels difficult; you do not need to give a complete account.
Your care team should adapt this support to you. Full care guidance and evidence
Acute experience
Several hours; highly variable
Pharmacokinetics
Parent drug and metabolite overlap. In the same 2024 model, median noribogaine peak occurred at 7.57 hours, with an interquartile range of 5.93 to 10.4 hours. Ibogaine concentrations were associated with QTc change and ataxia; the model does not predict an individual’s experience.
Inward absorption and bodily vulnerability
In Mash’s cohort, many people described a dreamlike period lasting 4 to 8 hours. Accounts include autobiographical scenes, symbolic or frightening imagery, and altered time or self perception. Others report little imagery. These are possible experiences, not milestones required for benefit.
Support during this stage
You may want quiet, company, reassurance, or help feeling connected to the room. Tell staff what feels useful. If you feel an urge to leave, talk with your facilitator about what is driving it and what would help you feel safer. An altered state can affect judgment and balance; ask the team to help you work through the next step without pressure or dismissal.
Your care team should adapt this support to you. Full care guidance and evidence
As intensity eases
Later hours into the next day
Pharmacokinetics
Noribogaine exposure can continue after the most vivid effects settle. Metabolism and interacting medicines change the duration of exposure. The end of imagery does not establish that cardiac or coordination effects have resolved.
A quieter experience is a transition
Some accounts move from vivid scenes toward quieter reflection; fatigue, sensitivity, or wakefulness may remain. There may be no clear dividing line. Schenberg’s qualitative work describes substantial physical and emotional difficulty alongside reflection, rather than one uniformly peaceful resolution.
Support during this stage
Feeling more like yourself can coexist with tiredness or unsteadiness. Let staff help you decide when to sit up, move, drink, and eat. You can describe what you remember, write a little, or rest. There is no need to settle the meaning of the experience before you have slept and recovered.
Your care team should adapt this support to you. Full care guidance and evidence
Following days
Recovery and continuing care
Pharmacokinetics
After direct noribogaine administration in healthy volunteers, mean elimination half lives ranged from 28 to 49 hours across dose groups. That study is different from ibogaine treatment. A half life describes concentration decline; it is not a discharge deadline or a duration of psychological benefit.
Persistent drug activity and changing needs
Sleep, energy, mood, certainty, and craving may change after the acute session. People need room for relief, disappointment, or mixed feelings without having those reactions labeled as success or failure. The guide does not assign everyone a fixed “gray day” or an afterglow.
Support during this stage
Plan for rest, meals, transport, and someone you can contact. Experiences that felt certain during the session can look different after sleep or when you return home. Give major decisions time. If mood, sleep, physical symptoms, or craving concern you, use the follow up plan rather than trying to make sense of everything alone.
Your care team should adapt this support to you. Full care guidance and evidence